Cassyni Biopharma的封面图片
Cassyni Biopharma

Cassyni Biopharma

生物技术研究

San Diego,CA 167 位关注者

Cassyni, acquired by Antharis Therapeutics in 2022, developed biotherapies against infectious and inflammatory diseases

关于我们

-Cassyni was successfully acquired by Antharis Therapeutics Inc, in July 2022. We developed monoclonal antibodies to fight human infectious and inflammatory diseases, and now continue these efforts under Antharis Therapeutics Inc.

所属行业
生物技术研究
规模
2-10 人
总部
San Diego,CA
类型
私人持股
创立
2020

地点

相似主页

查看职位